000755354 000__ 03148cam\a2200469Ii\4500
000755354 001__ 755354
000755354 005__ 20230306141844.0
000755354 006__ m\\\\\o\\d\\\\\\\\
000755354 007__ cr\cn\nnnunnun
000755354 008__ 160517s2016\\\\sz\a\\\\o\\\\\001\0\eng\d
000755354 019__ $$a950055713
000755354 020__ $$a9783319240978$$q(electronic book)
000755354 020__ $$a3319240978$$q(electronic book)
000755354 020__ $$z9783319240954
000755354 020__ $$z3319240951
000755354 035__ $$aSP(OCoLC)ocn949884250
000755354 035__ $$aSP(OCoLC)949884250$$z(OCoLC)950055713
000755354 040__ $$aN$T$$beng$$erda$$epn$$cN$T$$dGW5XE$$dN$T$$dIDEBK$$dCDX$$dEBLCP$$dOCLCF$$dYDXCP$$dAZU
000755354 049__ $$aISEA
000755354 050_4 $$aRE48
000755354 08204 $$a617.7/06$$223
000755354 24500 $$aAnti-angiogenic therapy in ophthalmology$$h[electronic resource] /$$cAndreas Stahl, editor.
000755354 264_1 $$aCham :$$bSpringer,$$c2016.
000755354 300__ $$a1 online resource (x, 193 pages) :$$billustrations.
000755354 336__ $$atext$$btxt$$2rdacontent
000755354 337__ $$acomputer$$bc$$2rdamedia
000755354 338__ $$aonline resource$$bcr$$2rdacarrier
000755354 4901_ $$aEssentials in ophthalmology,$$x1612-3212
000755354 500__ $$aIncludes index.
000755354 5050_ $$aRetinal Vascular Development -- Retinopathy of Prematurity -- Anti-Vascular Endothelial Growth Factor (VEGF) Treatment in Neovascular Age-Related Macular Degeneration: Outcomes and Outcome Predictors -- AREDS Supplementation and the Progression Towards Neovascular Exudative AMD -- VEGF-Inhibition in Macular Telangiectasia Type 2 -- Diabetic Retinopathy -- Retinal Vein Occlusion -- Pharmacokinetics of Intravitreally Applied VEGF Inhibitors -- Neovascular Glaucoma -- Corneal Neovascular Diseases -- Anti-Angiogenic Gene Therapy -- Basic Science and Challenges for Translation into the Clinic.
000755354 506__ $$aAccess limited to authorized users.
000755354 520__ $$aThis book provides a concise overview over the pathology of retinal angiogenic diseases and explains why anti-angiogenic therapy is effective in so many patients. The reader is guided through the various clinical indications for anti-angiogenic therapy and made aware of its merits as well as current challenges and limitations. It is explained how, since its introduction for the treatment of exudative age-related macular degeneration in 2006, anti-angiogenic therapy has revolutionized the way in which we treat a range of ocular diseases. All of the authors are established experts in their respective fields who share their extensive knowledge and clinical experience with the reader. This book is both a valuable introduction to anti-angiogenic therapy in ophthalmology and a day-to-day companion for all ophthalmologists seeing patients with some of the most prevalent retinal diseases.
000755354 588__ $$aOnline resource; title from PDF title page (SpringerLink, viewed May 19, 2016).
000755354 650_0 $$aEye$$xDiseases$$xTreatment.
000755354 650_0 $$aOphthalmology.
000755354 7001_ $$aStahl, Andreas,$$eeditor.
000755354 77608 $$iPrint version:$$z3319240951$$z9783319240954$$w(OCoLC)916592364
000755354 830_0 $$aEssentials in ophthalmology.
000755354 852__ $$bebk
000755354 85640 $$3SpringerLink$$uhttps://univsouthin.idm.oclc.org/login?url=http://link.springer.com/10.1007/978-3-319-24097-8$$zOnline Access$$91397441.1
000755354 909CO $$ooai:library.usi.edu:755354$$pGLOBAL_SET
000755354 980__ $$aEBOOK
000755354 980__ $$aBIB
000755354 982__ $$aEbook
000755354 983__ $$aOnline
000755354 994__ $$a92$$bISE